ADMA Biologics was trading poorly in early 2021, near $2 per share. My thesis centered on ADMA's asset value, including plasma centers, matching its enterprise value. Strong revenue growth, insider ...
We expect investors to focus on the sales performance of ADMA Biologics, Inc.’s ADMA portfolio of marketed products and other pipeline updates when it reports second-quarter 2024 results. Let’s see ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results